Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2026

Zhang Xiaoshen, Wen Yaokai, Wu Fengying, Jiang Yu, Lin Yuechun, Wang Lei, Zhou Fei, Shen Yue, Min Zhen, Li Wei, Liang Wenhua, He Jianxing, Zhou Caicun

Abstract excerpt

INTRODUCTION: The generation of drug-tolerant persister (DTP) cancer cells remains a major challenge in treating lung adenocarcinoma (LUAD) patients with EGFR tyrosine kinase inhibitors (TKIs), as these cells eventually drive drug resistance and disease progression. However, the mechanisms underlying DTP formation are poorly understood, limiting therapeutic options upon the emergence of DTP state or resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Glutathione Transferase

Share to Indoles

Share to Pyrimidines

Share to Tumor Microenvironment

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 41076079
DOI: 10.1016/j.jtho.2025.10.001

Genes

GSTA1
AXL
PROS1
RSPH1
EGFR
CALML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.PMID 41076079Read ↗

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Semantic proximity Read ↗

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read ↗

A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing dataSemantic proximity Read ↗

Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Target Therapy in Lung Adenocarcinoma Cell LinesSemantic proximity Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Semantic proximity Read ↗

Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug ToleranceSemantic proximity Read ↗

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read ↗

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.Semantic proximity Read ↗

Elevated Expression of <i>MALAT1</i> Contributes to the Survival of Drug-Tolerant Persister Cells Following Targeted Therapy in Lung AdenocarcinomaSemantic proximity Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.